Evaluating Clinical Routines for ICBT

NCT ID: NCT05321628

Last Updated: 2025-01-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

401 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-03

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of this study is to test the clinical benefits of an AI-based decision support tool (DST) and to evaluate how the DST affects therapists and their patients with depression, social anxiety, or panic disorder during 12 weeks of ICBT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The project aims to evaluate if therapist-supported ICBT with a DST that guides therapists in addition to a traditional therapist manual (the DST arm) are superior to ICBT using only the therapist manual (TRAD) arm.

The investigators hypothesize that DST, in comparison to TRAD, will:

* decrease the diagnose-specific symptoms during the treatment period, among patients identified to be at risk of failure (primary outcome),
* decrease the number of failed treatments among patients identified to be at risk,
* improve everyday functioning, health related quality of life, patient satisfaction, number of Adverse Events experienced by the patient, need for further treatment and sudden symptom changes among patients at risk,
* Increase the therapists' amount of interaction and time spent on patients at risk,
* increase the adherence to treatment among patients at risk, and
* improve levels of symptoms, functioning, interaction, and adherence when all patients (also those not at risk) are included
* make therapists overall more time efficient, defined as the ratio of 'decrease in symptoms / therapist time spent on patient'
* increase therapist experience of using the DST / the therapist manual, including higher perceived helpfulness and credibility and the overall experience of supervision, clinical routines, and guidance of their clinical decisions

The study is designed as a triple blind randomized controlled trial, where half of the therapists are allocated to DST and the other half to TRAD. Each patient is also randomized between those conditions. The therapists and patients will be blind to what group they are allocated to and the post-treatment assessors will also be blind to what group the patients belong to. The therapists and patients will know that they are randomized, but will be informed that the randomization concerns two different types of clinical routines and supervision, and will thus be blind to the true purpose of randomization. After randomization both groups will be informed that they are in the experimental group to lower the risk for nocebo effects.

The DST provides visual feedback about patient current adherence and symptoms levels, as well as predictions of final outcome and adherence, and also use four color indicators to guide the therapist:

* Green: Patient likely to succeed, consider spending less time on patient.
* Yellow: Prediction too uncertain to give guidance.
* Light Red: Patient likely to fail, consider adjustments.
* Dark Red: Patient very likely to fail, adjustments must be implemented.

A patient is considered to be at risk to fail if he/she gets a Light Red or Dark Red indication.

Primary outcome is the diagnose-specific symptom rating for each of the three ICBT-treatments that are used in the trial for Depression (MADRS-S), Panic Disorder (PDSS-SR), and Social Anxiety Disorder (LSAS-SR) respectively. Failed treatment are defined as being neither a responder (50% symptom reduction) nor a remitter (under a previously specified cut-off for each respective diagnose-specific symptom measure).

Primary analyses are performed according to intent-to-treat and, to handle missing data, with an HLM-model that test the interaction of Time x Arm and includes all available symptom data from pre to post, including weekly measures during treatment. It includes the estimated 50% of all patients that will be indicated as at risk (i.e. also control patients in TRAD, although their therapists never see the prediction because they do not use the DST). In a previous proof-of-concept trial the effect corresponding to our primary analysis was Cohen's d=0.59. To be conservative it was estimated to be 0.50. A power of 80% and an attrition of 20% would require 158 patients identified as at risk of failure, and thus 316 in total. To increase the less easily estimated power for secondary measures, the aim is to include 350 patients.

The trial will follow the guidelines of Good Clinical Practice adapted for psychological treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Panic Disorder Social Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
The therapists and patients will know that they are randomized, but will be informed that the randomization concerns two different types of clinical routines and supervision, and will thus be blind to the true purpose of randomization. Outcome assessors will not be informed that any randomization has occurred.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iCBT + Decision Support Tool

Internet-based Cognitive Behavioural Therapy where therapists have traditional clinical routines and supervision and also use a clinical decision support tool.

Group Type EXPERIMENTAL

Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool

Intervention Type BEHAVIORAL

Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.

Traditional iCBT

Internet-based Cognitive Behavioural Therapy with traditional clinical routines and supervision.

Group Type ACTIVE_COMPARATOR

Internet-based Cognitive Behavioural Therapy (iCBT)

Intervention Type BEHAVIORAL

iCBT, as described above, using only the traditional, detailed therapist manual.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool

Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.

Intervention Type BEHAVIORAL

Internet-based Cognitive Behavioural Therapy (iCBT)

iCBT, as described above, using only the traditional, detailed therapist manual.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older.
* Social anxiety, panic disorder or depression diagnosis.
* Stable or no antidepressant medication for at least 2 months.
* No diseases, disorders, or substance abuse that required other, immediate attention (e.g., severe depression or suicidality).
* Available time for treatment and acceptance of its format.
* Proficient in Swedish.
* No ongoing CBT.

Exclusion Criteria

* Not available for assessment and diagnostic telephone interview.
* Will not be in Sweden during the treatment period.
* Not able to receive text messages on a Swedish mobile phone.
* Not proficient in Swedish.
* No access to computer and internet.
* Not able to set aside about one hour a day to work on treatment.
* Bipolar disorder, if seeking depression treatment.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Stockholm

OTHER_GOV

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Viktor Kaldo

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Viktor Kaldo

Role: PRINCIPAL_INVESTIGATOR

Karolinska Institutet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Internet Psychiatry Unit, Psykiatri Sydväst, SLSO

Stockholm, Huddinge, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-05772

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ICBT for Antenatal Depression
NCT02366429 COMPLETED NA
Psilocybin-assisted CBT for Depression
NCT05227612 COMPLETED PHASE1
ICBT for Depression in Older Adults
NCT05269524 COMPLETED NA